Top Page
Wellnex Life Ltd
(Frankfurt:WNX)
Wellnex Life Ltd (WNX) vs. iShares MSCI Australia ETF (EWA)
Wellnex Life Ltd Business Overview & Revenue Model
Wellnex Life Ltd Financial Statement Overview
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 16.93M | 27.89M | 18.61M | 1.20M | 934.00K |
| Gross Profit | 4.11M | 4.75M | 4.50M | -165.00K | 447.00K |
| EBITDA | -10.57M | -6.82M | -6.35M | -18.41M | -9.45M |
| Net Income | -13.74M | -13.85M | -7.45M | -24.69M | -46.27M |
Balance Sheet | |||||
| Total Assets | 30.92M | 15.04M | 19.61M | 10.42M | 19.23M |
| Cash, Cash Equivalents and Short-Term Investments | 903.00K | 322.00K | 3.18M | 7.78M | 1.14M |
| Total Debt | 10.67M | 6.95M | 7.86M | 9.31M | 5.80M |
| Total Liabilities | 24.86M | 14.45M | 15.25M | 10.67M | 16.41M |
| Stockholders Equity | 6.06M | 594.00K | 4.36M | -249.00K | 18.63M |
Cash Flow | |||||
| Free Cash Flow | -6.82M | -6.19M | -8.65M | -5.17M | -31.34M |
| Operating Cash Flow | -6.82M | -6.19M | -8.61M | -4.38M | -7.57M |
| Investing Cash Flow | -13.42M | -2.20M | -3.65M | 9.45M | -16.92M |
| Financing Cash Flow | 20.82M | 5.53M | 7.66M | 1.65M | 7.28M |
Wellnex Life Ltd Technical Analysis
Wellnex Life Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
48 Neutral | AU$23.79M | ― | ― | -5.86% | 98.26% | ||
46 Neutral | C$204.55M | -3.23 | -23.14% | 1.87% | 20.75% | -0.36% | |
44 Neutral | AU$22.00M | ― | -47.74% | ― | 43.14% | 51.35% | |
39 Underperform | AU$19.99M | ― | -240.42% | ― | 14.41% | 76.26% | |
34 Underperform | AU$8.86M | ― | -105.17% | ― | -3.82% | 51.47% | |
31 Underperform | AU$4.23M | ― | ― | -16.29% | 58.77% |
Wellnex Life Ltd Corporate Events
Wellnex Life Ltd announced a change in the director’s interest, specifically regarding Eric Jiang’s indirect interest through Acee Group Pty Ltd. The change involved the expiry of 1,191 options, leaving the number of securities held unchanged. This update reflects routine adjustments in the company’s governance and does not indicate any immediate strategic shifts or impacts on stakeholders.
Wellnex Life Ltd announced a change in the director’s interest notice, specifically regarding Jeffrey Yeh’s indirect interests in securities through entities like Kirby Superannuation Pty Ltd, JYSF Management Pty Ltd, and Homart Group Pty Ltd. The change involved the expiry of options, resulting in no options held after the change, which may impact the company’s financial positioning and stakeholder interests.
Wellnex Life Limited announced a change in the director’s interest, specifically regarding George Karafotias, who disposed of 15,239 options. This change reflects an adjustment in the director’s holdings, leaving him with 149,825 fully paid ordinary shares. The expiration of these options may impact the company’s stock dynamics and investor perception, although no immediate financial implications were detailed.
Wellnex Life Limited has announced a change in the director’s interest, specifically involving Zlatko (Zack) Bozinovski. The change involves the expiry of options held by ZLJ Pty Ltd and Bozinovski, resulting in a reduction of options but no change in the number of shares held. This update reflects internal adjustments in the company’s management structure and may impact stakeholders’ perception of the company’s governance.
Wellnex Life Ltd announced the cessation of 550,000 securities due to the expiry of options without exercise or conversion as of July 20, 2025. This cessation may impact the company’s capital structure but is a routine financial adjustment, reflecting the company’s ongoing management of its securities and market positioning.
Wellnex Life Ltd has announced the cessation of certain securities, specifically convertible notes, which were repaid or redeemed without conversion as of March 24, 2025. This move could impact the company’s financial structure and may reflect strategic financial management decisions, potentially affecting stakeholders’ interests.
Wellnex Life Ltd announced the cessation of 5,055,123 securities due to the expiry of options or other convertible securities without exercise or conversion as of June 30, 2025. This development may impact the company’s capital structure and could influence its market positioning, as it reflects on the company’s strategic financial management and potential future capital-raising activities.
Wellnex Life Limited has divested the assets of The Iron Company brand to CW Retail Holdings Pty Ltd, part of the Chemist Warehouse group, as part of its strategy to focus on key brands like Pain Away, Wakey Wakey, and Nighty Night. This move follows an internal review post its AIM listing and aims to enhance trade activity within the Chemist Warehouse group, aligning with Wellnex’s renewed strategic focus.
Wellnex Life Limited (ASX: WNX) has announced the reinstatement of its securities to trading on the ASX following a suspension. This comes after the company addressed queries from the ASX regarding a previous announcement made on May 26, 2025. The lifting of the suspension is expected to positively impact the company’s market operations and reassure stakeholders about its compliance and transparency.
Wellnex Life Limited has retracted its previous announcement from May 26, 2025, due to concerns over the accuracy and reliability of prospective financial information in a research report by SP Angel, its UK broker. The company clarified that while it provided financial data to SP Angel, it does not endorse the report’s prospective financial information, leading to the retraction to maintain compliance with regulatory standards.
Wellnex Life Ltd has retracted financial forecasts previously shared in a research report produced by SP Angel, one of its UK-based brokers. The company had initially provided SP Angel with both public and internal financial targets for FY25 and FY26, which were used to generate independent forecasts. However, the company has since withdrawn these projections, which were based on assumptions of continued revenue growth, increased product distribution, and realization of sales targets.
The securities of Wellnex Life Ltd have been suspended from quotation by the ASX to prevent a disorderly or uninformed market. This suspension is pending the company’s response to queries from the ASX regarding a recent announcement titled ‘Letter to Shareholders’, which may impact the company’s market positioning and stakeholder relations.
Wellnex Life Limited has announced significant growth and strategic advancements, including a 46% increase in revenue and a 55% rise in gross profit for the period of January to April 2025 compared to the previous year. The company has also eliminated $13 million in liabilities, reducing financial risks and interest costs, and is focusing on profitable, sustainable growth by streamlining its offerings and concentrating on high-potential brands. This marks a pivotal point for Wellnex, as it aims to maximize shareholder value and achieve sustainable cash flow.
Wellnex Life Limited announced the cessation of George Tambassis as a director, effective from May 6, 2025. The notice indicates that Tambassis held no relevant interests in securities as a registered holder or through other entities, suggesting minimal immediate impact on the company’s operations or market positioning.
Wellnex Life Limited has announced changes to its board and management following a successful dual listing on the AIM Market of the London Stock Exchange. Non-Executive Chairman George Tambassis has resigned due to external commitments, and Andrew Vidler, an independent Non-Executive Director, will serve as interim Chairman. The company has also appointed Zack Bozinovski as joint CEO to focus on business growth and shareholder value. These changes aim to ensure a seamless transition and continued expansion in the healthcare market.